Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Celgene Corp (CELG) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 91,869,432
  • Shares Outstanding, K 775,120
  • Annual Sales, $ 9,256 M
  • Annual Income, $ 1,602 M
  • 36-Month Beta 1.75
  • Price/Sales 9.93
  • Price/Book 16.26

Price Performance

See More
Period Period Low Period High Performance
1-Month
100.92 +16.56%
on 11/04/16
127.00 -7.38%
on 11/09/16
+14.78 (+14.37%)
since 11/02/16
3-Month
96.93 +21.36%
on 10/25/16
127.00 -7.38%
on 11/09/16
+12.14 (+11.51%)
since 09/02/16
52-Week
93.05 +26.42%
on 02/03/16
127.00 -7.38%
on 11/09/16
+6.20 (+5.56%)
since 12/02/15

Most Recent Stories

More News
bluebird Stock Up on Positive Interim Multiple Myeloma Data

bluebird bio (BLUE) reported encouraging interim phase I data on its anti-BCMA CAR T cell candidate, bb2121, in relapsed/refractory multiple myeloma patients.

Here's Why Bluebird Bio (BLUE) is Rallying Today

On Thursday, shares of Bluebird Bio Inc. (BLUE) are rallying, up over 17% in midday trading after positive results came in for its experimental anti-BCMA CAR (chimeric antigen receptor) T-cell product...

NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day

NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day

Celgene vs. Regeneron: Which Stock is a Better Pick?

Both Celgene (CELG) and Regeneron (REGN) are Zacks Rank #2 (Buy) stocks; which one of these two stocks is a better choice for investors?

Biotech Stock Roundup: Acorda Stops Ampyra PSWD Development, CRL for Spectrum's Qapzola

Focus is back on pipeline and regulatory updates with the end of the third quarter earnings season and elections.

Nearly 350 Abstracts Evaluating Celgene Therapies to Be Presented at American Society of Hematology Annual Meeting (ASH)

Celgene Corporation (NASDAQ:CELG) today announced that data from nearly 350 abstracts, including more than 150 oral presentations, evaluating Celgene investigational agents and investigational...

Agios Presents Data from Dose Expansion Study of AG-120

Agios Pharmaceuticals, Inc. (AGIO) announced first data from a phase I study on AG-120.

Celgene Corporation to Webcast an Analyst and Investor Event from the American Society of Hematology Meeting in December

Celgene Corporation (NASDAQ:CELG) plans to webcast an analyst and investor event being held at the American Society of Hematology (ASH) meeting in San Diego on December 4. The webcast will...

Data on Early Onset of Efficacy for Oral OTEZLA(R) (apremilast) in Active Psoriatic Arthritis Presented at American College of Rheumatology

--Improvements in ACR20 and other measures of disease seen as early as week 2

Juno Therapeutics (JUNO) Q3 Loss Narrower than Expected

Juno Therapeutics Inc. (JUNO) reported a loss of 58 cents per share (including stock-based compensation expense) in the third quarter of 2016, narrower than the Zacks Consensus Estimate loss of 64 cents....

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Weakening.

See More

Business Summary

Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

See More

Support & Resistance

2nd Resistance Point 120.24
1st Resistance Point 118.94
Last Price 117.63
1st Support Level 116.78
2nd Support Level 115.92

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.